Sage Journals: Discover world-class research

Open access

Research article

First published 2024

Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR-positive and HER2-negative advanced breast cancer: results from a phase Ib study

Qingyuan Zhang, Pin Zhang, Min Yan [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2024

HR-positive/HER2-negative breast cancer arising in patients with or without BRCA2 mutation: different biological phenotype and similar prognosis

Pu-Chun Li, Yi-Fan Zhu, Jia-Ni Pan [...]

Therapeutic Advances in Medical Oncology

Retricted access

Research article

First published 2026

Predictive Value of Magee Equation 3 for Tumor and Axillary Response to Neoadjuvant Chemotherapy in HR-Positive,HER2-Negative Breast Cancer

Mustafa Onur Beştaş, Erkan Güler, Ahmet Dağ [...]

The American Surgeon™

Retricted access

Research article

First published 2025

Efficacy and safety of phosphoinositide 3-kinase inhibitors and AKT-inhibitors in combination with fulvestrant in PIK3CA mutated,HR-positive,HER2-negative invasive breast cancer: A systematic review

Chris Larck, Joseph B Elmes, R. Wesley Haynes [...]

Journal of Oncology Pharmacy Practice

Open access

Research article

First published 2025

A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease)

Bora Lim, Angela Marx, Megumi Kai [...]

Therapeutic Advances in Medical Oncology

Open access

Review article

First published 2023

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer

Mark Pegram, Richard Pietras, Chau T. Dang [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2025

Efficacy and Safety of Ribociclib Plus Endocrine Therapy Versus Endocrine Therapy Alone in HR-Positive/HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Reechashree Dhungana, Parikshit Prasai, Bishal Paudel [...]

Clinical Medicine Insights: Oncology

Open access

Research article

First published 2023

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+,HER2−,node-positive,high-risk early breast cancer

Shani Paluch-Shimon, Patrick Neven, Jens Huober [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2019

Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial

Susanne Crocamo, Renata Binato, Bruno de Paula [...]

Therapeutic Advances in Medical Oncology

Open access

Case report

First published 2024

Elacestrant plus alpelisib in an ESR1 and PIK3CA co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety

Ünal Metin Tokat, Şevval Nur Bilgiç, Esranur Aydın [...]

Therapeutic Advances in Medical Oncology

Search results